CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
Conditions
Brief summary
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
DRUGMS-553, DS1
Oral, Dose Schedule 1
DRUGMS-553, DS2
Oral, Dose Schedule 2
Sponsors
MingSight Pharmaceuticals, Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years or older. 2. Diagnosis of CLL or SLL: 1. History of histologically documented CLL or SLL that meets iwCLL diagnostic criteria according to the 2018 guidelines, and 2. Indication for treatment as defined by the 2018 iwCLL guidelines, or the need for disease reduction prior to allogeneic transplantation.-
Exclusion criteria
1. Current transformation of CLL/SLL non-Hodgkin lymphoma or Hodgkin lymphoma. 2. Active and uncontrolled autoimmune cytopenia(s).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The occurrence of AEs and SAEs, with abnormal laboratory tests results, abnormal physical examination findings, abnormal vital signs, and abnormal ECG readings | Through study completion, an average of 2 years |
Contacts
Primary ContactKai Zhang
Outcome results
None listed